SuperworthTeva Pharmaceutical Industries EPS TEVA
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- $0.60
- Latest quarter, Q2 FY26
- −$0.49
- −304% on a year earlier
- Fiscal year 2025
- $1.20
Teva Pharmaceutical Industries' earnings per share was $0.60 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.49, down 304% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.20 | n/a |
| FY2024 | −$1.45 | n/a |
| FY2023 | −$0.51 | n/a |
| FY2022 | −$2.12 | −658% |
| FY2021 | $0.38 | n/a |
| FY2020 | −$3.64 | n/a |
| FY2019 | −$0.92 | n/a |
| FY2018 | −$2.33 | n/a |
| FY2017 | −$16.27 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.49 | −304% | $0.60 | |
| Q1 FY26 | $0.31 | +72% | $1.33 | |
| Q4 FY25 | $0.41 | n/a | $1.20 | |
| Q3 FY25 | $0.37 | n/a | $0.60 | |
| Q2 FY25 | $0.24 | n/a | −$0.16 | |
| Q1 FY25 | $0.18 | n/a | −$1.15 | |
| Q4 FY24 | −$0.19 | −146% | −$1.45 | |
| Q3 FY24 | −$0.39 | −750% | −$0.85 | |
| Q2 FY24 | −$0.75 | n/a | −$0.40 | |
| Q1 FY24 | −$0.12 | n/a | −$0.43 | |
| Q4 FY23 | $0.41 | n/a | −$0.51 | |
| Q3 FY23 | $0.06 | +20% | −$2.02 |
Against its peers
Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TEVATeva Pharmaceutical Industries | $0.60 | |
| IQVIQVIA | $8.06 | +17% a year |
| MDLNMedline | n/m | |
| WATWaters | $4.01 | −64% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| AAgilent Technologies | $5.09 | +19% a year |
| ONCBeOne Medicines | $0.43 | |
| HUMHumana | $10.57 | −19% a year |
| EWEdwards Lifesciences | $1.74 | −75% a year |
| ILMNIllumina | $5.38 | −32% a year |
| BDXBecton, Dickinson and | $3.31 | −40% a year |
| Peer median | $5.09 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Teva Pharmaceutical Industries
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.